PCCA’s Post

Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate

In this interview with ONCOLife, our CEO Dr. Stacy Lindborg and leading gynecologic oncologist Dr. Premal Thaker engage in a thought-provoking discussion on #immunotherapy and recent advances in ovarian #cancer research, including key findings from the OVATION 2 study. They also explore how our therapy could offer potential advantages over the current standard of care and address the critical needs of those impacted by #ovariancancer. Read the full interview here: https://lnkd.in/dsf-G_YF #OvarianCancerAwareness #CancerResearch #Immunotherapy #WomensHealth

🚨 New #DiabetesDialogue! 🚨 Hear from John Buse, MD, PhD, as he discusses why he says the 2-part CATALYST trial might be the "biggest thing that I have ever done in my career" with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES. Get a deep dive into the trial, including part 2, which will examine use of mifepristone (Korlym; Corcept Therapeutics) among patients who screened positive for hypercortisolism. https://lnkd.in/et4uQuDg #Type2Diabetes #Hypercortisolism

In episode 5 Dr. John Marshall shares the latest #oncology buzz and talks about the crucial role of pharmacy benefit managers (PBMs) in medicine. He also discusses the recent FTC report, "Pharmacy Benefit Managers, the Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies." Don't miss this insightful discussion on how PBMs are shaping treatments and costs in healthcare today. Watch the full episode. Stay informed! https://lnkd.in/ghYFVTPA

I’m releasing my KPTI slides with Sohanya as the next CEO if Reshma leaves or prefers to just run Medical. Both Reshma & Sohanya are ready to run the company. Richard (current CEO’s) salary of $1-3M per annum can be removed from the books. This plus other key resource reallocation - specifically, eliminating the Commercial function and having my binary business part “Uncle Rolli Greer” return as Chief Business Officer to assume control of SINE REGIONAL EDUCATORS. We only need 9-11 for all of America to fix XPOVIO® (selinexor) HCP, focus on key opportunities within their states, and better focus for the forthcoming potential launches. This would also enable the company to save $25M cash and bring back the phase 2 trial to see if selinexor can Cure Glioblastoma . Here’s a sneak peak of the Green Karyopharm Therapeutics Inc. logo Nore that the first P is now capitalized. Uncle Rolli and I prefer to call it KaryoPharm Therapeutics (KPTI). It only costs $2500 to change a stock sum of. This way, we can shorten it to KPT or KAR on the Nasdaq if available. Tick tock, Richard Paulson! Patients are waiting. We need to fix KPTI once and for all. ~Jeff Conroy Global HC Analytics LLC Founder Email: jconroy@theghca.com https://lnkd.in/esCrjp3Q

ICLUSIG® (ponatinib) gets FDA nod as frontline therapy for rare leukaemia: Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic leukaemia (ALL). The US regulator has cleared Iclusig (ponatinib) with reduced-intensity chemo for adult patients with newly diagnosed Philadelphia chromosome-positive ALL (Ph+ ALL), a fast-progressing blood cancer that makes up around a quarter of adult ALL cases. It occurs when pieces of chromosomes 9 and 22 switch with each other to form abnormal structures and the development of the BCR-ABL1 kinase, which is targeted by Iclusig. https://lnkd.in/eKrE88ZG

The first pivotal trial of a CAR T cell therapy in first line will be given in community settings rather than exclusively in Centers of Excellence. It's an allogeneic product, meaning it's "off-the-shelf" ready. If this succeeds, it would address some critical limitations in CAR T cell therapy: individualized manufacturing bottlenecks (and costs due to non-scalability) and limited site availability associated with autologous cell therapies. Looking forward to the data disclosure in 2027! #Cancer #Oncology #CART #CellTherapies #Medicine https://lnkd.in/giFU2iZB +++ 👋 I’m Chris, a medical strategist, writer, and founder of Quill Science LLC. We use accurate and engaging storytelling to amplify the benefits of cutting-edge scientific and medical advances. 🌐 Check out www.quillscience.com and book a free discovery call. 💡 Follow me for science and medical news, perspectives, and career posts.

Vascular Ehlers Danlos Syndrome is a life-threatening #RareDisease, which is why Zevra Therapeutics is committed to bringing a new treatment to the #VEDS community. Through our Decentralized Study Evaluating Celiprolol on VEDS Related Events (DiSCOVER) clinical trial, we are investigating celiprolol as a potential therapy for VEDS. Want to know if you’re eligible? Learn more about our DiSCOVER trial and enroll here: https://bit.ly/3C305i8 #ClinicalTrial

Meet Kari, your guide to flawless skin at Skin Therapeutics! 💫 Dive into the details of how our Clear and Brilliant laser treatments can transform your skin by booking a session with Kari today. Don’t miss our special this month—4 sessions for just $1650 (originally $2000). Learn more about Kari’s expertise here. #ExpertCare #ClearAndBrilliant #SkinHealth

🔬 Exciting Updates in Clinical Trials! 🔬 🔹 Viridian Strive clinical trial is currently seeking Thyroid Eye Disease (TED) adult subjects! Eligible individuals can refer via the chat function on CockerhamMD.com for an intravenous dose of either 3 or 10 mg. Notably, there is no placebo arm for this trial. 🔹 Horizon/Amgen has successfully recruited their first subject for a clinical trial focusing on the transcutaneous delivery of a modified Tepezza molecule. The randomized process for this study is set to commence on July 9th. 🔹 In another recent development, the Genentech/Roche clinical trial is now live, with a primary focus on evaluating the efficacy of an IL6 monoclonal antibody. Stay tuned for more updates on these groundbreaking clinical trials! 🌟 #ClinicalTrials #Healthcare #MedicalResearch